StockData
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. (ALDX) stock

ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.69+0.02 (+3.63%)

Close on Nov 17, 2026Market cap $41.86MP/E –Yield –

Aldeyra Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Aldeyra Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$22.02M. For fiscal 2025 it was -$33.35M. The highest annual figure on record is -$1.71M in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$33.35M–
FY2024Dec 31, 2024-$43.21M–
FY2023Dec 31, 2023-$30.33M–
FY2022Dec 31, 2022-$56.64M–
FY2021Dec 31, 2021-$42.56M–
FY2020Dec 31, 2020-$37.49M–
FY2019Dec 31, 2019-$44.98M–
FY2018Dec 31, 2018-$29.86M–
FY2017Dec 31, 2017-$19.22M–
FY2016Dec 31, 2016-$15.15M–
FY2015Dec 31, 2015-$9.31M–
FY2014Dec 31, 2014-$4.78M–
FY2013Dec 31, 2013-$1.71M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.59M–
Q1 FY2026Mar 31, 2026-$5.11M–
Q4 FY2025Dec 31, 2025-$5.30M–
Q3 FY2025Sep 30, 2025-$7.02M–
Q2 FY2025Jun 30, 2025-$8.56M–
Q1 FY2025Mar 31, 2025-$12.47M–
Q4 FY2024Dec 31, 2024-$12.04M-2505.3%
Q3 FY2024Sep 30, 2024-$7.97M–
Q2 FY2024Jun 30, 2024-$13.22M–
Q1 FY2024Mar 31, 2024-$9.97M–
Q4 FY2023Dec 31, 2023$500.44K–
Q3 FY2023Sep 30, 2023-$8.02M–
Q2 FY2023Jun 30, 2023-$13.36M–
Q1 FY2023Mar 31, 2023-$9.44M–
Q4 FY2022Dec 31, 2022-$11.23M–
Q3 FY2022Sep 30, 2022-$12.57M–
Q2 FY2022Jun 30, 2022-$19.96M–
Q1 FY2022Mar 31, 2022-$12.87M–
Q4 FY2021Dec 31, 2021-$11.58M–
Q3 FY2021Sep 30, 2021-$8.43M–
Q2 FY2021Jun 30, 2021-$9.07M–
Q1 FY2021Mar 31, 2021-$13.47M–
Q4 FY2020Dec 31, 2020-$8.32M–
Q3 FY2020Sep 30, 2020-$6.24M–
Q2 FY2020Jun 30, 2020-$7.58M–
Q1 FY2020Mar 31, 2020-$15.36M–
Q4 FY2019Dec 31, 2019-$11.23M–
Q3 FY2019Sep 30, 2019-$8.32M–
Q2 FY2019Jun 30, 2019-$12.81M–
Q1 FY2019Mar 31, 2019-$12.63M–
Q4 FY2018Dec 31, 2018-$7.97M–
Q3 FY2018Sep 30, 2018-$7.69M–
Q4 FY2017Dec 31, 2017-$5.02M–
Q3 FY2017Sep 30, 2017-$4.71M–
Q2 FY2017Jun 30, 2017-$5.31M–
Q1 FY2017Mar 31, 2017-$4.19M–
Q4 FY2016Dec 31, 2016-$3.91M–
Q3 FY2016Sep 30, 2016-$3.50M–
Q2 FY2016Jun 30, 2016-$3.25M–

More Aldeyra Therapeutics figures

See a number that looks wrong?